{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:56Z","timestamp":1791839876026,"version":"4.3.4"},"reference-count":26,"publisher":"Endocrinology Research Centre","issue":"3","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>On December 3, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the safety and personalized use of tirzepatide (Tirzetta\u00ae) and semaglutide (Velgia\u00ae eco) in patients with overweight and obesity. Following the meeting, a consensus position was developed on the optimal use of incretin receptor agonists in real-world clinical practice.<\/jats:p>","DOI":"10.14341\/probl13784","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:08:54Z","timestamp":1779462534000},"page":"36-43","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":1,"title":["Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide"],"prefix":"10.14341","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-8702","authenticated-orcid":true,"given":"E. A.","family":"Troshina","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-2997","authenticated-orcid":true,"given":"M. B.","family":"Antsiferov","sequence":"additional","affiliation":[{"name":"Endocrinological Dispensary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-7619","authenticated-orcid":true,"given":"A. S.","family":"Ametov","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuing Professional Education"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-2021","authenticated-orcid":true,"given":"I. G.","family":"Bakulin","sequence":"additional","affiliation":[{"name":"St. Petersburg State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-4521","authenticated-orcid":true,"given":"G. R.","family":"Galstyan","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-887X","authenticated-orcid":true,"given":"T. N.","family":"Markova","sequence":"additional","affiliation":[{"name":"Russian University of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-6394","authenticated-orcid":true,"given":"T. I.","family":"Romantsova","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuing Professional Education"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-9381","authenticated-orcid":true,"given":"N. V.","family":"Mazurina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-4116","authenticated-orcid":true,"given":"O. M.","family":"Koteshkova","sequence":"additional","affiliation":[{"name":"Endocrinological Dispensary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5458","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Troshina EA, Antsiferov M.B., Ametov AS, Galstyan GR, Markova TN, Romantsova TI, Mazurina NV, Koteshkova OM. A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide. Problems of Endocrinology. 2025;71(5):19-30. (In Russ.)] doi: https:\/\/doi.org\/10.14341\/probl13677","DOI":"10.14341\/probl13677"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-16. doi: https:\/\/doi.org\/10.1056\/NEJMoa2206038","DOI":"10.1056\/NEJMoa2206038"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi: https:\/\/doi.org\/10.1001\/jama.2023.24945","DOI":"10.1001\/jama.2024.2603"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. doi: https:\/\/doi.org\/10.1038\/s41591-024-03015-5","DOI":"10.1038\/s41591-024-03015-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. doi: https:\/\/doi.org\/10.1136\/bmj-2023-076410","DOI":"10.1136\/bmj-2023-076410"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. doi: https:\/\/doi.org\/10.1056\/NEJMoa2416394","DOI":"10.1056\/NEJMoa2416394"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Du Y, Zhang M, Wang Z, et al. A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data. J Diabetes Investig. 2024. doi: https:\/\/doi.org\/10.1111\/jdi.14229","DOI":"10.1111\/jdi.14229"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105","DOI":"10.1111\/dom.14551"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1):145. doi: https:\/\/doi.org\/10.3390\/jcm12010145","DOI":"10.3390\/jcm12010145"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Salukhov VV, Galstyan GR, Khalimov IS, Bakulin IG, Cherkashin DV, Shadrichev FE, Sukhotskaia NA. Practical application of semaglutide: From evidence-based research to expert decisions. Meditsinskiy sovet = Medical Council. 2025;(6):14-29 (In Russ.)] doi: https:\/\/doi.org\/10.21518\/ms2025-185","DOI":"10.21518\/ms2025-185"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211","DOI":"10.7326\/0003-4819-143-3-200508020-00006"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hsu WH, Geng JH, Wu PY, et al.. Metabolic syndrome is associated with gastroesophageal reflux disease in a large Taiwanese population study. Int J Med Sci. 2025 Feb 28;22(7):1555-1561","DOI":"10.7150\/ijms.109616"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring). 2013;21(2):284-90","DOI":"10.1002\/oby.20279"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Parra-Landazury NM, Cordova-Gallardo J, M\u00e9ndez-S\u00e1nchez N. Obesity and Gallstones. Visc Med. 2021;37(5):394-402","DOI":"10.1159\/000515545"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gebhard RL, Prigge WF, Ansel HJ, et al. The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss. Hepatology. 1996;24(3):544-8","DOI":"10.1053\/jhep.1996.v24.pm0008781321"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Troshina EA, Suplotova LA, Dzgoeva FKh, et al. The opportunities to improve therapy adherence in patients with overweight and obesity in real clinical practice. Problems of Endocrinology. 2026;72(1):89-98. (In Russ.)] doi: https:\/\/doi.org\/10.14341\/probl13737","DOI":"10.14341\/probl13737"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Stokes C, et al. Ursodeoxycholic Acid and Diets Higher in Fat Prevent Gallbladder Stones During Weight Loss: A Meta-analysis of Randomized Controlled Trials. Clin Gastroenterol Hepatol. 2014;12:1090\u20131100","DOI":"10.1016\/j.cgh.2013.11.031"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Mechanick JI, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures \u2013 2019 update. Surg Obes Relat Dis. 2020;16(2):175\u2013247","DOI":"10.1016\/j.soard.2019.10.025"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bischoff SC, Barazzoni R, Busetto L, et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN\/UEG guideline. United European Gastroenterol J. 2022 Aug. doi: https:\/\/doi.org\/10.1002\/ueg2.12280","DOI":"10.1016\/j.clnu.2022.07.003"},{"key":"ref20","unstructured":"Ministerstvo zdravoohraneniya Rossijskoj federacii. Klinicheskie rekomendacii \u00abNealkogol\u2019naya zhirovaya bolezn\u2019 pecheni u vzroslyh\u00bb, Rossiya, 2024 (In Russ.)]"},{"key":"ref21","unstructured":"Ministerstvo zdravoohraneniya Rossijskoj federacii. Klinicheskie rekomendacii \u00abZhelchnokamennaya bolezn\u2019\u00bb, Rossiya, 2024. (In Russ.)]"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Jiang K, Chen B, Lou D, et al. Systematic review and meta-analysis: association between obesity\/overweight and surgical complications in IBD. Int J Colorectal Dis. 2022;37(7):1485-1496","DOI":"10.1007\/s00384-022-04190-y"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Stamboltsyan V.Sh., Bakulin I.G., Aslanov B.I., Kirillova A.A. Inflammatory bowel diseases: epidemiology and risk factors (review). Koloproktologia. 2024;23(4):148-158 (In Russ.)] doi: https:\/\/doi.org\/10.33878\/2073-7556-2024-23-4-148-158","DOI":"10.33878\/2073-7556-2024-23-4-148-158"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Gorelik Y, Ghersin I, Lujan R, et al. GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN. J Crohns Colitis. 2025;19(4): jjae160. doi: https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae160","DOI":"10.1093\/ecco-jcc\/jjae160"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gofron KK, Wasilewski A, Ma\u0142gorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17(8):1303. doi: https:\/\/doi.org\/10.3390\/nu17081303","DOI":"10.3390\/nu17081303"},{"key":"ref26","unstructured":"Sherf-Dagan S, et al. Micronutrient deficiencies in patients after bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2023;24(1):e13523"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13784\/11011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:48:42Z","timestamp":1785221322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,22]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13784","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}